MIAMI, FLORIDA — August 28, 2025 — Leads & Copy — Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced new in vitro results expanding understanding of its lead drug candidate, Telomir-1, which targets cancer, aging, and age-related diseases.
Studies by Eurofins Discovery showed Telomir-1 inhibits UTX (KDM6A), an enzyme that affects DNA methylation and histone marks, influencing gene activation. Abnormal UTX activity can silence protective genes and activate harmful ones, seen in cancer, autoimmune disease, and neurodegeneration. UTX also affects stem cell renewal and tissue repair.
Telomir-1’s ability to block UTX is a step forward, as UTX was considered undruggable. Telomir-1 may reset faulty DNA methylation patterns, restore gene control, support stem cell function, and counteract age-related epigenetic drift.
Telomir-1 also inhibits FBXL10 (KDM2B), FBXL11 (KDM2A), and JMJD3 (KDM6B), which are involved in cancer, neurodegeneration, metabolic dysfunction, inflammation, and aging. It reactivated tumor suppressor genes like STAT1 and TMS1 in prostate cancer models.
Telomir-1 did not show activity against GCN5L2 (KAT2A), potentially offering a cleaner safety margin than existing epigenetic drugs.
Telomir-1 also demonstrated inhibitory activity against Tankyrases, regulating the Wnt/β-catenin pathway. Unlike potent Tankyrase inhibitors, Telomir-1 may cut off cancer’s fuel line without disrupting telomere biology.
Previously, Telomir-1 elongated telomeres, reversed DNA methylation, and restored gene regulation in a Werner Syndrome model.
Dr. Itzchak Angel, Chief Scientific Advisor at Telomir, added “UTX and JMJD3 have long been labeled undruggable despite their central role in cancer, inflammation, and aging. The fact that Telomir-1 engages both enzymes with high potency, while sparing opposing targets such as GCN5L2, is a significant mechanistic breakthrough. It highlights Telomir-1’s potential to reprogram gene control selectively and safely.”
Helga Moya can be reached at info@telomirpharma.com or (786) 396-6723.
Source: Telomir Pharmaceuticals, Inc.
